Real-world effectiveness of fecal microbiota transplantation for first or second Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.cgh.2024.05.038
Economic and Chronologic Optimization of Fecal Donors Screening Process.|https://dx.doi.org/10.1177/23814683241254809
Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy.|https://dx.doi.org/10.1002/imt2.200
Cyclic diguanylate differentially regulates the expression of virulence factors and pathogenesis-related phenotypes in Clostridioides difficile.|https://dx.doi.org/10.1016/j.micres.2024.127811
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence.|https://dx.doi.org/10.3390/microorganisms12061206
Integrated Safety and Efficacy Analyses of PhaseÂ 3 Trials of a Microbiome Therapeutic for Recurrent CDI.|https://dx.doi.org/10.1007/s40121-024-01007-z
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile.|https://dx.doi.org/10.1128/msphere.00273-24
